News stories about Karyopharm Therapeutics (NASDAQ:KPTI) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.2337282040676 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Karyopharm Therapeutics (NASDAQ:KPTI) traded up $0.51 during trading hours on Friday, reaching $10.52. 251,600 shares of the company traded hands, compared to its average volume of 184,363. The firm has a market cap of $512.85, a PE ratio of -3.95 and a beta of 4.08. Karyopharm Therapeutics has a 1 year low of $7.48 and a 1 year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities research analysts anticipate that Karyopharm Therapeutics will post -2.58 earnings per share for the current fiscal year.
Several equities analysts recently commented on the stock. Royal Bank of Canada reiterated a “buy” rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, December 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $17.33.
In other news, SVP Christopher Brett Primiano sold 27,042 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $10.28, for a total value of $277,991.76. Following the completion of the transaction, the senior vice president now owns 11,381 shares in the company, valued at approximately $116,996.68. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of $9.16, for a total transaction of $91,600.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares of the company’s stock, valued at approximately $4,782,829.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,000 shares of company stock valued at $630,069. Corporate insiders own 14.71% of the company’s stock.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.